Dr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin.

Memorial Sloan-Kettering Cancer Center medical oncologist Dr. Greg Riely explains how testing for specific mutations in patients with advanced NSCLC can guide prognosis and treatment recommendations.

HER2 inhibitors have been successfully used to combat breast cancer, but research has shown that a small percentage of lung cancer patients have a HER2 mutation as well. Dr. Leena Gandhi talks about the role that HER2 drugs may play to fight lung cancer.

[powerpress]

Drs. Ross Camidge and Corey Langer offer their perspectives on the most encouraging emerging targets that could become valuable additions to our lung cancer treatment menu in the next several years.

[powerpress]

By now, most patients (and hopefully, all oncologists!) are familiar with the significance of EGFR mutations in non-small cell lung cancer (NSCLC). The discovery of ALK mutations and the successful use of crizotinib in this setting has also been big news in the lung cancer world. I'd like to bring everyone up to date on two lesser known abnormalities that can occur in non-small cell lung cancer: HER2 and BRAF mutations.